WednesdayJul 17, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is…

Continue Reading

MondayJul 08, 2024 12:00 pm

Astiva Health Inc. Leading the Way as Record Number of People Choose Medicare Advantage Plans

For the first time in Medicare’s history, more than half of all eligible people with Medicare are enrolled in private Medicare Advantage plans Enrollment in Medicare Advantage programs is projected to grow from 54% of the eligible population in 2024 to 60% by the end of the decade Astiva Health has developed one of the most diverse networks in Southern California and offers a selection of benefits tailored to the specialized needs of its members According to a recent KFF report, a record number of people enrolled in private Medicare Advantage plans last year (https://ibn.fm/YEpRJ). That trend bodes well for Astiva Health,…

Continue Reading

FridayJul 05, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023 CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment. The data was presented by Dr. Karen Ho, Clene’s Vice President…

Continue Reading

FridayJun 28, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

Buntanetap is designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43 The study demonstrated significant efficacy and safety for buntanetap in a subgroup of early Alzheimer’s patients in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a recognized genetic factor linked to Alzheimer’s Annovis Bio has been selected to present detailed data from its Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 June is Alzheimer’s & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer’s disease and other forms of dementia, as well as the importance of…

Continue Reading

WednesdayJun 26, 2024 2:00 pm

BioMedNewsBreaks – Tivic Health(R) Systems (NASDAQ: TIVC) Names New Board Member

Tivic Health(R) Systems (NASDAQ: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of Christina Valauri to the company’s board of directors, effective July 1, 2024. “Over the past year, as an advisor to our Board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders,” TIVC Chair of the Board Sheryle Bolton…

Continue Reading

TuesdayJun 25, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Reveals Important Findings From HEALEY ALS Platform Trial

Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” showcased survival follow-up data CNM-Au8 was found to be safe and well-tolerated during the OLE Clene (NASDAQ: CLNN), through its wholly owned subsidiary, Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). This week, Clene unveiled new…

Continue Reading

TuesdayJun 25, 2024 9:00 am

HealthLynked Corp. (HLYK) Digitizes and Streamlines Process of Obtaining Medical Records with New Cutting-Edge Feature Integrated with DocuSign

HealthLynked, a leading provider of healthcare technology solutions, recently launched its new online medical record request form, integrated with DocuSign The new feature allows patients to seamlessly and securely request their medical records from doctors’ offices, hospitals, and laboratories with just a few clicks Through the feature, HealthLynked aims to solve inefficiencies and security issues affecting the flow of health information, helping patients share their medical records with their doctors directly The HIPAA, through the Privacy Rule, aims to allow the flow of health information that can help health care providers to provide high-quality health care and to protect the…

Continue Reading

MondayJun 24, 2024 11:15 am

Astiva Health Inc. Dedicated to Serving Growing Number of Older Adults Facing Mental-Health Challenges

Many older adults are at risk of developing mental-health conditions, including depression and anxiety disorders NCOA reports that “fewer than 50% of older adults with mental and/or substance-use disorders receive treatment” Astiva Health is committed to providing strategic, enhanced mental-health services for seniors to help them identify and effectively treat mental-health challenges As baby boomers continue to reach their “golden” years, the number of older adults grappling with mental illness also continues to increase. Astiva Health is committed to providing enhanced mental-health services for its members, as more seniors face mental disorders. “The world’s population is ageing fast,” reports the World Health Organization…

Continue Reading

ThursdayJun 20, 2024 12:00 pm

Astiva Health Inc. Solutions Include Growing Number of Activity Centers Focused on Serving Unique Needs of Seniors

Astiva Health Inc. is expanding services, offering healthcare solutions precisely targeted at growing senior demographic “NPJ Aging” reports that U.S. is undergoing a demographic and health transformation that will have profound implications for its healthcare system and society Astiva’s activity centers are designed to be a hub for seniors, providing a space for health education, wellness activities and community building As a record number of people become seniors and enter the season of their lives when quality health care becomes increasingly important, Astiva Health is expanding its services and offering healthcare solutions precisely targeted at this growing demographic. A fast-growing…

Continue Reading

TuesdayJun 18, 2024 12:00 pm

Clene Inc. (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference

Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience Clene has conducted several clinical trials to test the efficacy of CNM-Au8(R), focusing on the diseases amyotrophic lateral sclerosis and multiple sclerosis CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals attributed to CNM-Au8 Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000